Literature DB >> 26777728

Reprogramming the T Cell Response to Tuberculosis.

Joshua S Woodworth1, Peter Andersen2.   

Abstract

Coscolla, Copin et al. recently used comparative genomics of M. tuberculosis (Mtb) strains to show that most human T cell-recognized epitopes are hyperconserved, but bona fide variable epitopes also exist. This identification of two sets of antigens implies opposing evolutionary processes and will have an important impact on tuberculosis (TB) vaccine strategy and design.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26777728      PMCID： PMC4738003          DOI： 10.1016/j.it.2015.12.009

Source DB:  PubMed          Journal:  Trends Immunol        ISSN： 1471-4906            Impact factor:   16.687


  10 in total

1.  IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge.

Authors:  Shabaana A Khader; Guy K Bell; John E Pearl; Jeffrey J Fountain; Javier Rangel-Moreno; Garth E Cilley; Fang Shen; Sheri M Eaton; Sarah L Gaffen; Susan L Swain; Richard M Locksley; Laura Haynes; Troy D Randall; Andrea M Cooper
Journal:  Nat Immunol       Date:  2007-03-11       Impact factor: 25.606

Review 2.  The balance between protective and pathogenic immune responses in the TB-infected lung.

Authors:  Ian M Orme; Richard T Robinson; Andrea M Cooper
Journal:  Nat Immunol       Date:  2015-01       Impact factor: 25.606

3.  Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved.

Authors:  Iñaki Comas; Jaidip Chakravartti; Peter M Small; James Galagan; Stefan Niemann; Kristin Kremer; Joel D Ernst; Sebastien Gagneux
Journal:  Nat Genet       Date:  2010-05-23       Impact factor: 38.330

4.  Protective CD4 T cells targeting cryptic epitopes of Mycobacterium tuberculosis resist infection-driven terminal differentiation.

Authors:  Joshua S Woodworth; Claus Sindbjerg Aagaard; Paul R Hansen; Joseph P Cassidy; Else Marie Agger; Peter Andersen
Journal:  J Immunol       Date:  2014-02-26       Impact factor: 5.422

5.  Control of chronic mycobacterium tuberculosis infection by CD4 KLRG1- IL-2-secreting central memory cells.

Authors:  Thomas Lindenstrøm; Niels Peter Hell Knudsen; Else Marie Agger; Peter Andersen
Journal:  J Immunol       Date:  2013-05-15       Impact factor: 5.422

6.  Impact of in vitro evolution on antigenic diversity of Mycobacterium bovis bacillus Calmette-Guerin (BCG).

Authors:  Richard Copin; Mireia Coscollá; Sebastien Gagneux; Joel D Ernst; Efstratios Efstathiadis
Journal:  Vaccine       Date:  2014-09-06       Impact factor: 3.641

Review 7.  Tuberculosis vaccines--rethinking the current paradigm.

Authors:  Peter Andersen; Joshua S Woodworth
Journal:  Trends Immunol       Date:  2014-05-27       Impact factor: 16.687

8.  M. tuberculosis T Cell Epitope Analysis Reveals Paucity of Antigenic Variation and Identifies Rare Variable TB Antigens.

Authors:  Mireia Coscolla; Richard Copin; Jayne Sutherland; Florian Gehre; Bouke de Jong; Olumuiya Owolabi; Georgetta Mbayo; Federica Giardina; Joel D Ernst; Sebastien Gagneux
Journal:  Cell Host Microbe       Date:  2015-11-11       Impact factor: 21.023

9.  Immunological consequences of intragenus conservation of Mycobacterium tuberculosis T-cell epitopes.

Authors:  Cecilia S Lindestam Arlehamn; Sinu Paul; Federico Mele; Charlie Huang; Jason A Greenbaum; Randi Vita; John Sidney; Bjoern Peters; Federica Sallusto; Alessandro Sette
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-29       Impact factor: 11.205

10.  ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre- and post-exposure tuberculosis vaccination.

Authors:  Truc Hoang; Claus Aagaard; Jes Dietrich; Joseph P Cassidy; Gregory Dolganov; Gary K Schoolnik; Carina Vingsbo Lundberg; Else Marie Agger; Peter Andersen
Journal:  PLoS One       Date:  2013-12-12       Impact factor: 3.240
  10 in total
  10 in total

1.  "The Impact of Mycobacterium tuberculosis Immune Evasion on Protective Immunity: Implications for TB Vaccine Design" - Meeting report.

Authors:  Cesar Boggiano; Katrin Eichelberg; Lakshmi Ramachandra; Jaqueline Shea; Lalita Ramakrishnan; Samuel Behar; Joel D Ernst; Steven A Porcelli; Markus Maeurer; Hardy Kornfeld
Journal:  Vaccine       Date:  2017-05-02       Impact factor: 3.641

2.  Identification of Mycobacterial Ribosomal Proteins as Targets for CD4+ T Cells That Enhance Protective Immunity in Tuberculosis.

Authors:  Steven C Kennedy; Alison J Johnson; Sushma Bharrhan; Cecilia S Lindestam Arlehamn; Jiayong Xu; Scott J Garforth; John Chan; William R Jacobs; Alessandro Sette; Steven C Almo; Steven A Porcelli
Journal:  Infect Immun       Date:  2018-08-22       Impact factor: 3.441

Review 3.  Moving tuberculosis vaccines from theory to practice.

Authors:  Peter Andersen; Thomas J Scriba
Journal:  Nat Rev Immunol       Date:  2019-09       Impact factor: 53.106

4.  Protection associated with a TB vaccine is linked to increased frequency of Ag85A-specific CD4(+) T cells but no increase in avidity for Ag85A.

Authors:  Hannah J Metcalfe; Sabine Steinbach; Gareth J Jones; Tim Connelley; W Ivan Morrison; Martin Vordermeier; Bernardo Villarreal-Ramos
Journal:  Vaccine       Date:  2016-08-04       Impact factor: 3.641

5.  New Genome-Wide Algorithm Identifies Novel In-Vivo Expressed Mycobacterium Tuberculosis Antigens Inducing Human T-Cell Responses with Classical and Unconventional Cytokine Profiles.

Authors:  Mariateresa Coppola; Krista E van Meijgaarden; Kees L M C Franken; Susanna Commandeur; Gregory Dolganov; Igor Kramnik; Gary K Schoolnik; Inaki Comas; Ole Lund; Corine Prins; Susan J F van den Eeden; Gro E Korsvold; Fredrik Oftung; Annemieke Geluk; Tom H M Ottenhoff
Journal:  Sci Rep       Date:  2016-11-28       Impact factor: 4.379

6.  Efficacy Testing of H56 cDNA Tattoo Immunization against Tuberculosis in a Mouse Model.

Authors:  Anouk C M Platteel; Natalie E Nieuwenhuizen; Teresa Domaszewska; Stefanie Schürer; Ulrike Zedler; Volker Brinkmann; Alice J A M Sijts; Stefan H E Kaufmann
Journal:  Front Immunol       Date:  2017-12-11       Impact factor: 7.561

7.  Ag85A-specific CD4+ T cell lines derived after boosting BCG-vaccinated cattle with Ad5-85A possess both mycobacterial growth inhibition and anti-inflammatory properties.

Authors:  Hannah J Metcalfe; Lucia Biffar; Sabine Steinbach; Efrain Guzman; Tim Connelley; Ivan Morrison; H Martin Vordermeier; Bernardo Villarreal-Ramos
Journal:  Vaccine       Date:  2018-04-11       Impact factor: 3.641

8.  Identification and Evaluation of Novel Protective Antigens for the Development of a Candidate Tuberculosis Subunit Vaccine.

Authors:  Elena Stylianou; Rachel Harrington-Kandt; Julia Beglov; Naomi Bull; Nawamin Pinpathomrat; Gwendolyn M Swarbrick; Deborah A Lewinsohn; David M Lewinsohn; Helen McShane
Journal:  Infect Immun       Date:  2018-06-21       Impact factor: 3.441

9.  Immunization by Replication-Competent Controlled Herpesvirus Vectors.

Authors:  David C Bloom; Robert K Tran; Joyce Feller; Richard Voellmy
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

Review 10.  Advancing Immunotherapeutic Vaccine Strategies Against Pulmonary Tuberculosis.

Authors:  Sam Afkhami; Anne Drumond Villela; Michael R D'Agostino; Mangalakumari Jeyanathan; Amy Gillgrass; Zhou Xing
Journal:  Front Immunol       Date:  2020-09-09       Impact factor: 7.561
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.